PE20030545A1 - Formulaciones de jarabe de ribavirina - Google Patents
Formulaciones de jarabe de ribavirinaInfo
- Publication number
- PE20030545A1 PE20030545A1 PE2002001063A PE2002001063A PE20030545A1 PE 20030545 A1 PE20030545 A1 PE 20030545A1 PE 2002001063 A PE2002001063 A PE 2002001063A PE 2002001063 A PE2002001063 A PE 2002001063A PE 20030545 A1 PE20030545 A1 PE 20030545A1
- Authority
- PE
- Peru
- Prior art keywords
- ribavirin
- agent
- syrup formulations
- formulation
- rivarin
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 2
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title 1
- 229960000329 ribavirin Drugs 0.000 title 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title 1
- 239000006188 syrup Substances 0.000 title 1
- 235000020357 syrup Nutrition 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 230000003139 buffering effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 abstract 1
- 239000000796 flavoring agent Substances 0.000 abstract 1
- 235000019634 flavors Nutrition 0.000 abstract 1
- 235000003599 food sweetener Nutrition 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 abstract 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 abstract 1
- 239000003765 sweetening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
SE REFIERE A UNA FORMULACION LIQUIDA QUE COMPRENDE 1)20 g/l A 65 g/l DE RIVARINA; 2)UN SISTEMA DE TAMPONAMIENTO QUE COMPRENDE: i)5 g/l DE CITRATO DE SODIO DIHIDRATO; Y ii)2 g/l DE ACIDO CITRICO ANHIDRO; 3)POR LO MENOS UN AGENTE EDULCORANTE; 4)100 g/l DE UN AGENTE QUE INCREMENTA LA VISCOSIDAD FARMACEUTICAMENTE ACEPTABLE, TAL COMO PROPILEN GLICOL USP; Y, 5)UN AGENTE ANTIMICROBIANO. DONDE, DICHA FORMULACION TIENE UN pH ENTRE 4,8 Y 5,3 Y ES ESTABLE AL ALMACENAMIENTO POR UN TIEMPO DE AL MENOS 18 MESES Y POSEE SABOR MEJORADO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33475101P | 2001-10-31 | 2001-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030545A1 true PE20030545A1 (es) | 2003-06-19 |
Family
ID=23308655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002001063A PE20030545A1 (es) | 2001-10-31 | 2002-10-29 | Formulaciones de jarabe de ribavirina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6790837B2 (es) |
| EP (1) | EP1480653B1 (es) |
| JP (1) | JP4393192B2 (es) |
| KR (1) | KR100929320B1 (es) |
| CN (1) | CN1319535C (es) |
| AR (1) | AR037131A1 (es) |
| AT (1) | ATE439847T1 (es) |
| AU (1) | AU2002350081B2 (es) |
| BR (1) | BR0213536A (es) |
| CA (1) | CA2464151C (es) |
| CO (1) | CO5570681A2 (es) |
| CY (1) | CY1110524T1 (es) |
| DE (1) | DE60233438D1 (es) |
| DK (1) | DK1480653T3 (es) |
| ES (1) | ES2330419T3 (es) |
| HU (1) | HU229259B1 (es) |
| MX (1) | MXPA04004068A (es) |
| NO (1) | NO334361B1 (es) |
| NZ (1) | NZ531967A (es) |
| PE (1) | PE20030545A1 (es) |
| PL (1) | PL205342B1 (es) |
| PT (1) | PT1480653E (es) |
| SI (1) | SI1480653T1 (es) |
| TW (1) | TWI259082B (es) |
| WO (1) | WO2003037312A2 (es) |
| ZA (1) | ZA200402975B (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7691880B2 (en) * | 2003-10-08 | 2010-04-06 | Mallinckrodt Inc. | Methylphenidate solution and associated methods of administration and production |
| US20060110479A1 (en) * | 2004-11-24 | 2006-05-25 | Mitra Shankar K | Natural composition for curing hepatitis-B, methods for making the same and pharmaceutical formulations thereof |
| AR067630A1 (es) * | 2007-07-12 | 2009-10-21 | Novartis Ag | Soluciones farmaceuticas de telbivudina y metodo de tratamiento |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| DE112012003510T5 (de) | 2011-10-21 | 2015-03-19 | Abbvie Inc. | Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| CN104023726A (zh) | 2011-10-21 | 2014-09-03 | 艾伯维公司 | 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333) |
| WO2013149258A2 (en) | 2012-03-30 | 2013-10-03 | Charles Drew University of Medicine and Science | Compositions and methods for treating or preventing metabolic syndrome disorders |
| US20140271923A1 (en) | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| EA201892448A1 (ru) | 2016-04-28 | 2019-06-28 | Эмори Юниверсити | Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения |
| US20190336443A1 (en) * | 2018-05-03 | 2019-11-07 | Navinta Iii Inc | Ready-To-Use Liquid Parenteral Formulations Of Ribavirin |
| CN109568257A (zh) * | 2018-12-24 | 2019-04-05 | 江西润泽药业有限公司 | 一种利巴韦林注射液及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) * | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| JPS58198416A (ja) * | 1982-05-15 | 1983-11-18 | Ota Seiyaku Kk | セフアレキシンドライシロツプ剤の製造法 |
| JPS63177797A (ja) * | 1987-01-19 | 1988-07-21 | Ajinomoto Co Inc | リボ−ス−１−リン酸及びリバビリンの製造法 |
| US4880784A (en) * | 1987-12-21 | 1989-11-14 | Brigham Young University | Antiviral methods utilizing ribofuranosylthiazolo[4,5-d]pyrimdine derivatives |
| CA2188297C (en) * | 1994-04-28 | 2006-12-19 | Frederick Herman Hausheer | Lactone stable formulation of camptothecin or 7-ethyl camptothecin |
| US5767097A (en) * | 1996-01-23 | 1998-06-16 | Icn Pharmaceuticals, Inc. | Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes |
| US6423695B1 (en) * | 1998-01-13 | 2002-07-23 | Ribapharm, Inc. | Cytokine related treatments of disease |
| US6132758A (en) * | 1998-06-01 | 2000-10-17 | Schering Corporation | Stabilized antihistamine syrup |
-
2002
- 2002-10-29 PE PE2002001063A patent/PE20030545A1/es not_active Application Discontinuation
- 2002-10-29 AR ARP020104108A patent/AR037131A1/es active IP Right Grant
- 2002-10-30 TW TW091132150A patent/TWI259082B/zh not_active IP Right Cessation
- 2002-10-31 JP JP2003539656A patent/JP4393192B2/ja not_active Expired - Fee Related
- 2002-10-31 MX MXPA04004068A patent/MXPA04004068A/es active IP Right Grant
- 2002-10-31 DK DK02786612T patent/DK1480653T3/da active
- 2002-10-31 CN CNB028217233A patent/CN1319535C/zh not_active Expired - Fee Related
- 2002-10-31 DE DE60233438T patent/DE60233438D1/de not_active Expired - Lifetime
- 2002-10-31 WO PCT/US2002/034898 patent/WO2003037312A2/en not_active Ceased
- 2002-10-31 CA CA2464151A patent/CA2464151C/en not_active Expired - Fee Related
- 2002-10-31 ES ES02786612T patent/ES2330419T3/es not_active Expired - Lifetime
- 2002-10-31 PT PT02786612T patent/PT1480653E/pt unknown
- 2002-10-31 BR BR0213536-1A patent/BR0213536A/pt not_active IP Right Cessation
- 2002-10-31 US US10/285,119 patent/US6790837B2/en not_active Expired - Lifetime
- 2002-10-31 PL PL372224A patent/PL205342B1/pl not_active IP Right Cessation
- 2002-10-31 NZ NZ531967A patent/NZ531967A/en not_active IP Right Cessation
- 2002-10-31 EP EP02786612A patent/EP1480653B1/en not_active Expired - Lifetime
- 2002-10-31 HU HU0600300A patent/HU229259B1/hu unknown
- 2002-10-31 AT AT02786612T patent/ATE439847T1/de active
- 2002-10-31 AU AU2002350081A patent/AU2002350081B2/en not_active Ceased
- 2002-10-31 KR KR1020047005865A patent/KR100929320B1/ko not_active Expired - Fee Related
- 2002-10-31 SI SI200230853T patent/SI1480653T1/sl unknown
-
2004
- 2004-04-19 ZA ZA2004/02975A patent/ZA200402975B/en unknown
- 2004-04-27 CO CO04038162A patent/CO5570681A2/es active IP Right Grant
- 2004-05-28 NO NO20042228A patent/NO334361B1/no not_active IP Right Cessation
-
2009
- 2009-10-29 CY CY20091101125T patent/CY1110524T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE871335L (en) | Steroid formulations. | |
| PE20030545A1 (es) | Formulaciones de jarabe de ribavirina | |
| AR073793A1 (es) | Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido | |
| ES2110377T1 (es) | Formulacion galenica de fenofibrato y aplicacion de la misma. | |
| TNSN04023A1 (fr) | Formulation de suspension orale stabilisee | |
| CY1120513T1 (el) | Υψηλης συμπυκνωσης συνθεση μινοξιδιλης | |
| IL145185A0 (en) | Echinocandin pharmaceutical formulations containing micelle-forming surfactants | |
| ATE307808T1 (de) | Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser | |
| ITMI20021392A1 (it) | Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' | |
| EE9900589A (et) | Farmatseutilised kompositsioonid limaskestale kandmiseks | |
| CA2396927A1 (en) | Stabilized ascorbic acid solutions; use thereof; process for their obtention; and formulations comprising the same | |
| ES8608888A1 (es) | Una formulacion parenteral endoparasiticida y ectoparasiticida | |
| EA200300406A1 (ru) | Фармацевтическая композиция дронедарона для парентерального введения | |
| NO950134L (no) | Formuleringer for oralt administrerte farmasöytiske midler | |
| NZ334836A (en) | Liquid alendronate formulations and their use in preventing bone resorption | |
| WO2004069187A3 (en) | Drug formulation and delivery using crystalline methylated cyclodextrins | |
| AR030715A1 (es) | Sistemas saborizantes para composiciones farmaceuticas y metodos para hacer dichas composiciones | |
| NO20021476L (no) | Farmasöytisk b¶rerformulering | |
| JPS57146722A (en) | Pharmaceutical preparation having improved absorption | |
| US5874450A (en) | Intranasal formulations for promoting sleep and method of using the same | |
| ES2310550T3 (es) | Preparacion liquida acuosa de pranoprofeno. | |
| PE20020055A1 (es) | Formulaciones estables liquidas y solidas que comprenden una antihistamina no sedante y un descongestionante nasal | |
| ES2128353T3 (es) | Composicion topica que contiene penciclovir. | |
| ES8304429A1 (es) | Un procedimiento para la preparacion de soluciones minerales acuosas estables de levonantradol y n-metil-levonantradol. | |
| ES2238418T3 (es) | Solucion acuosa estable de desoxifructosazina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |